DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Nulojix (Belatacept) - Published Studies


Nulojix Related Published Studies

Well-designed clinical trials possibly related to Nulojix (Belatacept)

Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. [2013]

A randomized controlled trial to evaluate inhibition of T-cell costimulation in allergen-induced airway inflammation. [2013]

Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study). [2012]

Improvements in participation in usual daily activities in patients with rheumatoid arthritis treated with abatacept. [2011]

Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale. [2010]

Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment. [2010]

Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. [2010]

Sequential use of biologic therapy in rheumatoid arthritis. [2010]

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). [2010]

Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. [2009]

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. [2009]

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. [2009]

Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial. [2008]

Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept. [2008]

Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. [2008]

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. [2008]

Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. [2007]

Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. [2007]

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. [2007]

Abatacept. [2006]

Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. [2006]

Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. [2006]

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. [2005]

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. [2005]

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. [2003]

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. [2002]

Other research related to Nulojix (Belatacept)

Belatacept for kidney transplant recipients. [2014]

Transcriptional profiling of belatacept and calcineurin inhibitor therapy in renal allograft recipients. [2014]

Prospective monitoring of cytomegalovirus, Epstein-Barr virus, BK virus, and JC virus infections on belatacept therapy after a kidney transplant. [2014]

Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. [2014]

Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes. [2011]

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). [2010]

Technology evaluation: Belatacept, Bristol-Myers Squibb. [2005]

Costimulation blockade with belatacept in renal transplantation. [2005]

Other possibly related research studies

Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. [2012]

Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. [2012]

My treatment approach to rheumatoid arthritis. [2012]

Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom. [2012]

Abatacept for Crohn's disease and ulcerative colitis. [2012]

Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data? [2012]

Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients. [2011]

A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. [2011]

Adverse effects of biologics: a network meta-analysis and Cochrane overview. [2011]

Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. [2011]

Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs. [2011]

Comparative effectiveness of rheumatoid arthritis therapies. [2010]

Evaluation of disease activity assessments in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy: analyses of abatacept clinical trial data. [2010]

Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. [2010]

Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. [2010]

Abatacept for rheumatoid arthritis: a Cochrane systematic review. [2010]

Abatacept for rheumatoid arthritis. [2009]

Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks? [2009]

[Biological agents]. [Article in Japanese] [2009]

[Efficacy of new biologics on bone destruction in rheumatoid arthritis]. [Article in Japanese] [2009]

[A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation] [2009]

Validation of a simple activity participation measure for rheumatoid arthritis clinical trials. [2009]

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. [2009]

The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. [2008]

Selective costimulation modulation with abatacept: a look at quality-of-life outcomes in patients with rheumatoid arthritis. [2009]

Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. [2008]

The multi-faceted assessment of independence in patients with rheumatoid arthritis: preliminary validation from the ATTAIN study. [2008]

An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. [2008]

Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. [2007]

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. [2008]

Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis. [2007]

Efficacy results from pivotal clinical trials with abatacept. [2007]

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. [2008]

Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. [2008]

Abatacept: a novel therapy approved for the treatment of patients with rheumatoid arthritis. [2007]

Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. [2007]

Item response theory methods can improve the measurement of physical function by combining the modified health assessment questionnaire and the SF-36 physical function scale. [2007]

Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. [2007]

Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. [2006]

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. [2006]

Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities. [2006]

Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. [2005]

Projecting long-term graft and patient survival after transplantation. [2014]

Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). [2014]

Biological therapies in rheumatic diseases. [2013]

Effect of abatacept on immunogenicity of vaccines in individuals with type 1 diabetes. [2013]

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. [2014]

Challenges and opportunities in SLE clinical trials. [2013]

Drug therapy in undifferentiated arthritis: a systematic literature review. [2013]

Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial. [2013]

Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States during 1983-2009. [2013]

Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. [2013]

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. [2013]

Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. [2013]

The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug. [2014]

Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease. [2014]

Are sample sizes of randomized clinical trials in rheumatoid arthritis too large? [2014]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017